上海家化(600315.SH):子公司擬申請合計2693萬英鎊年度授信額度
格隆匯2月19日丨上海家化(600315.SH)公佈,公司全資子公司Success Bidco 2 Limited、Mayborn UK Limited、Gro-Group International Limited擬分別與英國匯豐銀行有限公司簽署授信協議,申請年度總金額為2693萬英鎊的授信額度,用於補充流動資金、購買利率風險對衝、外匯風險對衝工具、開具海關保函、公司卡等業務。
在上述年度授信總額度內,公司子公司可向銀行借款用於補充流動資金、購買利率風險對衝工具、外匯風險對衝工具、開具海關保函、公司卡等業務,有利於滿足子公司正常生產經營資金的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.